**Core Concept**
The Philadelphia chromosome is a characteristic chromosomal abnormality resulting from a reciprocal translocation between chromosomes 9 and 22, t(9;22). This genetic anomaly is most commonly associated with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The translocation leads to the fusion of the BCR and ABL1 genes, creating a chimeric protein that disrupts normal cell cycle regulation and promotes uncontrolled cell proliferation.

**Why the Correct Answer is Right**
The presence of the Philadelphia chromosome in leukemia cells is a hallmark of CML or ALL. The BCR-ABL1 fusion protein, resulting from the t(9;22) translocation, activates the ABL1 tyrosine kinase, leading to continuous signaling for cell growth and division. This results in an overproduction of mature and immature white blood cells, which can lead to a significant increase in the white blood cell count. A complete blood count (CBC) would most likely show a marked elevation in the white blood cell count, with a predominance of mature and immature granulocytes.

**Why Each Wrong Option is Incorrect**
**Option A:** A normal CBC would not be expected in a patient with leukemia, especially one with a t(9;22) translocation.
**Option B:** Anemia, thrombocytopenia, or a decrease in white blood cell count is not characteristic of CML or ALL with the Philadelphia chromosome.
**Option C:** While some patients with CML may develop a myeloid blast crisis, this option is too specific and does not accurately describe the typical CBC findings in a patient with a t(9;22) translocation.

**Clinical Pearl / High-Yield Fact**
The Philadelphia chromosome is a crucial diagnostic marker for CML and ALL, and its presence can guide treatment decisions, including the use of tyrosine kinase inhibitors that target the BCR-ABL1 fusion protein.

**Correct Answer: C. A marked elevation in the white blood cell count with a predominance of mature and immature granulocytes.**